A capital-intensive clinical-stage biopharmaceutical firm advancing proprietary therapeutic candidates with no current product revenue but significant potential upside upon successful trial completion.
If Serina successfully advances its clinical programs and secures FDA approval for any drug candidates, the company could experience explosive growth in revenue and market capitalization as it transitions to profitability. The current low market valuation reflects minimal revenue but offers significant upside potential if key milestones are achieved and partnerships are struck. Investors may benefit from early exposure to transformative therapies before commercial success is realized.
The company faces existential risk due to its severe cash constraints, with a retained earnings deficit of -$44.3M and operating losses deepening the hole year over year. Without imminent product approvals or major licensing deals, Serina will likely require dilutive financing rounds that could erode shareholder value further. The high probability of clinical trial failure in late-stage oncology development makes this an extremely speculative investment with limited downside protection.
Serina Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious unmet medical needs, primarily in oncology and rare diseases. The company operates within the competitive biotechnology sector, leveraging advanced research platforms to advance candidate drugs from discovery through clinical trials toward commercialization. With minimal current revenue, Serina relies heavily on external financing to fund its extensive R&D pipeline and operational expenses.
Serina Therapeutics reported a net loss of $11.2M in the latest period, reflecting its status as a clinical-stage entity investing heavily in research and development while generating negligible revenue of only $56k. The company's cash flow from financing activities provided $13.2M in proceeds, partially offsetting the substantial cash burn from operations which totaled -$17.1M. Despite these financial challenges, management continues to advance its pipeline with share-based compensation covering $2.6M and R&D spending at $7.5M.
The biotechnology industry is characterized by high barriers to entry, long development cycles, and significant regulatory scrutiny from agencies like the FDA. Companies in this space often operate at a loss for years while investing in research and development to bring novel therapies to market. Success depends on achieving clinical trial success rates that remain historically low, with only a small percentage of drug candidates reaching commercialization.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $34.0K | $142.0K | $56.0K |
| Cost of Revenue | $13.0K | $40.0K | $0 |
| Gross Profit | $21.0K | $102.0K | $56.0K |
| Operating Expenses | $7.0M | $10.1M | $17.1M |
| Operating Income | $-7.0M | $-9.9M | $-17.0M |
| R&D | $1.0M | $734.0K | $7.5M |
| G&A | $6.0M | $9.3M | $9.6M |
| Stock-Based Comp | $760.0K | $648.0K | $2.6M |
| D&A | — | — | $194.0K |
| Amortization | $132.0K | $131.0K | $100.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $17.5M | $24.7M | $5.9M |
| Interest Expense | $3.3M | $4.9M | — |
| Pre-Tax Income | $10.5M | $14.8M | $-11.1M |
| Income Tax | $21.0M | $29.6M | $0 |
| Continuing Ops | $-10.5M | $-14.8M | $-11.1M |
| Discontinued Ops | $0 | $0 | $-66.0K |
| Net Income | $-10.5M | $-14.8M | $-11.2M |
| Minority Interest | $-60.0K | $-8.0K | $-66.0K |
| Net to Common | $-10.5M | $-14.8M | $-11.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $2.5M | $754.0K | $5.7M |
| Cash & Equivalents | $645.0K | $345.0K | $3.7M |
| Accounts Receivable | $4.0K | $57.0K | — |
| Prepaid Expenses | $1.8M | $352.0K | $2.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $788.0K | $11.2M | $1.0M |
| PP&E (Net) | — | — | $501.0K |
| Intangibles | $738.0K | $607.0K | — |
| Operating Leases | — | — | $461.0K |
| Other LT Assets | $50.0K | $10.6M | $86.0K |
| Total Assets | $3.2M | $12.0M | $6.7M |
| Current Liabilities | $10.1M | $5.9M | $2.4M |
| Accounts Payable | $568.0K | $1.4M | $744.0K |
| Current Leases | — | — | $192.0K |
| Other Current Liab | $9.2M | $4.0M | $1.0K |
| Long-Term Liabilities | $10.5M | $693.0K | $3.9M |
| LT Operating Leases | — | — | $268.0K |
| Other LT Liab | — | $-2.00B | $3.6M |
| Total Liabilities | $20.6M | $6.6M | $6.2M |
| Shareholders' Equity | $-17.3M | $5.4M | $508.0K |
| Paid-In Capital | $99.0M | $136.5M | $45.0M |
| Retained Earnings | $-116.2M | $-131.0M | $-44.3M |
| Total L&E | $3.2M | $12.0M | $6.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-10.5M | $-14.8M | $-11.2M |
| Non-Cash Adjustments | $6.1M | $7.4M | $-6.4M |
| Working Capital Changes | $-1.5M | $-345.0K | $431.0K |
| Cash from Operations | $-5.9M | $-7.8M | $-17.1M |
| Cash from Investing | $0 | $-10.0M | $-22.0K |
| Cash from Financing | $6.0M | $17.5M | $13.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $61.0K | $-300.0K | $-3.9M |
| Beginning Cash | $634.0K | $695.0K | $7.6M |
| Ending Cash | $695.0K | $395.0K | $3.7M |
Primary business segment involves the discovery and development of novel drug candidates targeting oncology and rare disease indications. Secondary activities include strategic partnerships or licensing agreements that may generate non-recurring income, though none are currently materialized in recent financials. The company also incurs standard corporate overhead including general and administrative costs, share-based compensation, and research and development expenses typical of pre-commercial biotechs.
Significant cash burn with limited reserves, as operating losses exceeded $11M recently while cash equivalents stood at only $3.7M. High dependency on successful external financing events like equity offerings or debt issuance given negative cash flow from operations of -$17.1M. Clinical trial failures could result in substantial write-offs and halt development of expensive asset candidates with no revenue generation. Regulatory hurdles including FDA approval processes pose uncertainty regarding market access for future products.
Proprietary drug candidates with differentiated mechanisms of action that address significant unmet medical needs in oncology and rare diseases. Strong intellectual property portfolio protecting key therapeutic assets against generic competition or patent challenges. Experienced management team with a track record of navigating the complex regulatory landscape to advance clinical programs.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.